BLAC (Bellevue Life Sciences Acquisition) EBIT per Share : $-0.40 (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition EBIT per Share?

Bellevue Life Sciences Acquisition's EBIT per Share for the three months ended in Sep. 2024 was $-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.40.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's EBIT per Share or its related term are showing as below:

BLAC's 3-Year EBIT Growth Rate is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 3.65
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Bellevue Life Sciences Acquisition's EBIT for the three months ended in Sep. 2024 was $-0.45 Mil.

Bellevue Life Sciences Acquisition EBIT per Share Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition EBIT per Share Chart

Bellevue Life Sciences Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.24

Bellevue Life Sciences Acquisition Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial									-0.05	-0.12	-0.08	-0.10	-0.11

Bellevue Life Sciences Acquisition EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bellevue Life Sciences Acquisition's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.831	/	7.720
=	-0.24

Bellevue Life Sciences Acquisition's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.454	/	4.041
=	-0.11

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40

Bellevue Life Sciences Acquisition (NAS:BLAC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Bellevue Life Sciences Acquisition EBIT per Share Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellevue Life Sciences Acquisition Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004

Website

https://www.bellevuespac.com

Bellevue Life Sciences Acquisition Corp is a blank check company.

Executives

David Jin Yoo	officer: Chief Financial Officer	(135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang	director, 10 percent owner, officer: Chief Executive Officer	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc	10 percent owner	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed	other: Director Nominee	2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang	director	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts	other: Director Nominee	10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004